ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, has announced the expansion of its network of exclusive distributors. The distributors will offer the DeepChek® technology, a suite of Sanger & NGS assays and software systems, to laboratories performing infectious diseases genotyping. With the new expansion, ABL Diagnostics’ network of professional partners now covers 47 countries across Africa, Asia, Europe, the Middle East, and South America.
“We are extremely pleased to rely on a growing number of local distributors, trained on the ABL Diagnostics technology and able to offer innovative assays and end-to end solutions to microbiology labs on a worldwide basis,” said Mr. Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics.
Christopher Busuttil, Chief Visionary Officer at Evolve Ltd (Malta) commented: “Partnering with ABL to provide critical quality and dependable diagnostic tests on time and at the right price in these times of great financial instabilities and logistical problems was no easy feat. With determination and a focus on our philosophy of making a positive impact on society through science, the decision to exceed customer requirements and expectations was easier, even if it meant putting less focus on immediate financial returns. We are all grateful to do our part in combating Covid-19 and to continue being a key stakeholder in patients’ health.”
ABL Diagnostics’ network includes local distributors such as Bionova (Bolivia), which started working with ABL to provide NGS solutions for their clients. “We already have clients implementing HIV NGS testing in Bolivia,” said Aldo Vacaflores, CEO and founder of Bionova.
The company is also reinforcing its commercial presence in various Western European countries, such as France, Spain, Germany, Sweden, and Denmark. They are planning to strengthen their team to actively start operations in Asia and in the USA in 2024.
ABL Diagnostics offers innovative and proprietary molecular biology assays and end-to-end solutions intended to be used for molecular detection by Polymerase Chain Reaction (PCR) – UltraGene® and for genotyping through DNA sequencing – DeepChek®. The company commercializes its products on a worldwide basis through its own sales team and through its network of exclusive distributors.
ABL Diagnostics, based in Woippy, is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR001400AHX6).
Today, ABL Diagnostics has announced the expansion of its exclusive distributors network that will offer the DeepChek® technology to laboratories performing infectious diseases genotyping. The network of professional partners now covers 47 countries across Africa, Asia, Europe, the Middle East, and South America.
“We are extremely pleased to rely on a growing number of local distributors, trained on the ABL Diagnostics technology and able to offer innovative assays and end-to end solutions to microbiology labs on a worldwide basis,” said Mr. Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics.
Christopher Busuttil, Chief Visionary Officer at Evolve Ltd (Malta) commented that partnering with ABL to provide diagnostic tests in this time of great financial instabilities and logistical problems was no easy feat. “We are all grateful to do our part in combating Covid-19 and to continue being a key stakeholder in patients’ health,” he added.
ABL Diagnostics offers proprietary molecular biology assays and end-to-end solutions intended to be used for molecular detection by Polymerase Chain Reaction (PCR) – UltraGene® and for genotyping through DNA sequencing – DeepChek®. The company commercializes its products on a worldwide basis through its own sales team and through its network of exclusive distributors.
The company is also reinforcing its commercial presence in various Western European countries, such as France, Spain, Germany, Sweden, and Denmark. They are planning to strengthen their team to actively start operations in Asia and in the USA in 2024. ABL Diagnostics is a public company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR001400AHX6).
ABL Diagnostics has announced the expansion of its network of exclusive distributors, allowing them to offer the DeepChek® technology to laboratories performing infectious diseases genotyping. The network of professional partners now covers 47 countries across Africa, Asia, Europe, the Middle East, and South America.
“We are extremely pleased to rely on a growing
